Ann Surg:术后并发症严重影响患者生存

2016-10-14 MedSci MedSci原创

调查RAS突变分析时代中,术后并发症对结直肠癌肝转移(CLM)患者的预后影响。已知术后并发症已与多种恶性肿瘤的癌症特异性结局有关。我们确定了575例已知RAS突变状态、在2008到2014年行肝切除的CLM患者。根据综合并发症指数评分(CCI)计算术后并发症得分,使用中性粒细胞/淋巴细胞比率(NLR)作为术前和术后患者的全身炎症反应指标。CLM患者切除后生存情况根据CCI分层(高,≥26.2;低,

调查RAS突变分析时代中,术后并发症对结直肠癌肝转移(CLM)患者的预后影响。

已知术后并发症已与多种恶性肿瘤的癌症特异性结局有关。

研究人员确定了575例已知RAS突变状态、在2008到2014年行肝切除的CLM患者。根据综合并发症指数评分(CCI)计算术后并发症得分,使用中性粒细胞/淋巴细胞比率(NLR)作为术前和术后患者的全身炎症反应指标。CLM患者切除后生存情况根据CCI分层(高,≥26.2;低,<26.2)。

88名患者CCI得分高,487名患者CCI得分低。CCI得分高的患者中,肝切除术后患者的无复发生存率(RFS)和肿瘤特异性生存率(CSS)更差(RFS,3年:26% vs. 41%, P = 0.003; CSS,5年:46% vs. 64%, P = 0.003)。肝切除术后3个月,高CCI值与高NLR值(>5)相关(OR 3.99, P <0.001)。五个因素是与较差的CSS相关:高CCI值(HR 1.61, P = 0.022),原发性淋巴结阳性(HR 1.70, P = 0.003),多个CLM(HR 1.72, P = 0.001),CLM≥3厘米(HR 1.73,P<0.001),RAS突变(HR 2.04, P <0.001)。CCI是比NLR更敏感、特异性和精确的RFS和CSS预测指标。

高CCI值是CLM患者切除术后较差RFS和CSS的预测指标。术后并发症对癌症生存的影响超过了患者结局对其的直接影响。

原始出处:


Yamashita, Suguru MD, PhD; Sheth, Rahul A. MD; Niekamp, Andrew S. MD; Aloia, Thomas A. MD; Chun, Yun Shin MD; Lee, Jeffrey E. MD; Vauthey, Jean-Nicolas MD; Conrad, Claudius MD, PhD.Comprehensive Complication Index Predicts Cancer-specific Survival After Resection of Colorectal Metastases Independent of RAS Mutational Status.Annals of Surgery:Post Author Corrections: October 4, 2016

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1932557, encodeId=f9be193255e97, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Thu Feb 16 00:53:00 CST 2017, time=2017-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757746, encodeId=26541e57746bb, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sat Apr 08 13:53:00 CST 2017, time=2017-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148738, encodeId=892d148e3852, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Oct 16 07:19:03 CST 2016, time=2016-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148142, encodeId=c489148142ec, content=会影响的, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0df71676643, createdName=1de2495dm19(暂无匿称), createdTime=Fri Oct 14 13:13:23 CST 2016, time=2016-10-14, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1932557, encodeId=f9be193255e97, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Thu Feb 16 00:53:00 CST 2017, time=2017-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757746, encodeId=26541e57746bb, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sat Apr 08 13:53:00 CST 2017, time=2017-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148738, encodeId=892d148e3852, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Oct 16 07:19:03 CST 2016, time=2016-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148142, encodeId=c489148142ec, content=会影响的, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0df71676643, createdName=1de2495dm19(暂无匿称), createdTime=Fri Oct 14 13:13:23 CST 2016, time=2016-10-14, status=1, ipAttribution=)]
    2017-04-08 丁鹏鹏
  3. [GetPortalCommentsPageByObjectIdResponse(id=1932557, encodeId=f9be193255e97, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Thu Feb 16 00:53:00 CST 2017, time=2017-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757746, encodeId=26541e57746bb, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sat Apr 08 13:53:00 CST 2017, time=2017-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148738, encodeId=892d148e3852, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Oct 16 07:19:03 CST 2016, time=2016-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148142, encodeId=c489148142ec, content=会影响的, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0df71676643, createdName=1de2495dm19(暂无匿称), createdTime=Fri Oct 14 13:13:23 CST 2016, time=2016-10-14, status=1, ipAttribution=)]
    2016-10-16 doctorJiangchao

    继续学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1932557, encodeId=f9be193255e97, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Thu Feb 16 00:53:00 CST 2017, time=2017-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757746, encodeId=26541e57746bb, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sat Apr 08 13:53:00 CST 2017, time=2017-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148738, encodeId=892d148e3852, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Oct 16 07:19:03 CST 2016, time=2016-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148142, encodeId=c489148142ec, content=会影响的, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0df71676643, createdName=1de2495dm19(暂无匿称), createdTime=Fri Oct 14 13:13:23 CST 2016, time=2016-10-14, status=1, ipAttribution=)]
    2016-10-14 1de2495dm19(暂无匿称)

    会影响的

    0

相关资讯

CSCO 2016:徐瑞华解读——转移性结直肠癌维持治疗指南

在厦门召开的第19届CSCO年会上,《结直肠癌姑息与靶向》专场,中山大学肿瘤防治中心徐瑞华教授为现场嘉宾解读转移性结直肠癌维持治疗中国专家共识。转移性结直肠癌维持治疗中国专家共识徐瑞华教授首先,什么是维持治疗?维持治疗是指:一线治疗一段时间后,达到最佳疗效且处于疾病稳定状态时,采用低强度、低毒性的药物持续治疗,以达到延长患者的无进展生存期,减少不良反应,延缓肿瘤相关症状的复发时间,提高患者生活质量

CSCO 2016:牛!这才是代表中国水平的临床试验!

导读:中国临床试验正在走向世界最强音!我国临床试验的起步虽晚于西方国家,但近年来,在我国医疗工作者及科研工作者的不断努力下,我国的临床试验飞速发展,不断进入新的高度。在本次CSCO盛会上,很多专家展示了他们的临床试验结果,让我们看到了我国临床鼓舞人心的世界强音。本篇报道向大家详细介绍中山大学附属六院的邓艳红教授团队张剑威博士所展示的他们团队的一项临床研究,即在局部进展期直肠癌接受新辅助治疗之后

JAMA Oncol:同样的治疗方案,不同部位的结肠癌,疗效却相反

转移性结直肠癌(mCRC)存在异质性;不同结肠区域来源的原发肿瘤,其临床和分子也是不同的。 研究对象来自于CRYSTAL试验(氟尿嘧啶、亚叶酸和伊立替康(FOLFIRI)+西妥昔单抗,作为转移性结直肠癌的一线治疗)和FIRE-3试验(FOLFIRI+西妥昔单抗 vs.FOLFIRI+贝伐单抗,治疗转移性结直肠癌癌),探究原发肿瘤对RAS野生型(wt) mCRC患者的预后和预测价值。 将

2016NCCN临床实践指南——遗传家族高风险评估-结直肠癌(2016.V2)发布

2016年9月,美国国家综合癌症网络(NCCN)发布了结直肠癌遗传/家族高风险评估指南2016年第2版。全文获取:下载地址:指南下载 (需要扣积分2分, 梅斯医学APP免积分下载) 

Int J Epidemiol:震惊!闹饥荒也会增加结直肠癌风险

人在生长发育过程中,营养不足也可能增加未来生活中的结直肠癌风险。 本研究纳入了1944年至1945年(荷兰饥荒年)期间、7906名0-21岁女性,这些参与者在1993年至1997年加入了Prospect-EPIC研究。我们使用Cox比例风险分析,调整潜在的混杂因素后,评估自我报告的饥荒暴露程度和不同暴露年龄,与结直肠癌(近端、远端结肠和直肠)风险之间的联系。 中位数随访17.3年过程中

盘点:“低脂饮食”真的很健康吗?

不知道大家有没有关注过超市某一条通道旁边写着“健康食品”的标牌,如果有的话,那么货架上摆放的大概就是低脂、富含纤维素的零食了。 低脂饮食究竟是否真的健康?尚存在争议。 【1】低脂饮食可延长ER-乳腺癌患者生存 研究纳入2437 I期到IIIA期乳腺癌患者,其中,1579例雌激素受体阳性患者,478例雌激素受体阴性患者,362例雌雄激素受体均阴性患者,年龄48-79岁之间,并接